Publications

2024

Liolios C., Bouziotis D., Sihver W., Schäfer M., Lambrinidis G., Salvanou E.-A., Bauder-Wüst U., Benesova M., Kopka K., Kolocouris A., Bouziotis P.
Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer Targeting Prostate Cancer
(2024) ACS Medicinal Chemistry Letters, 15 (11), 1970 - 1978.
DOI: 10.1021/acsmedchemlett.4c00324

Winter R.C., Amghar M., Wacker A.S., Bakos G., Taş H., Roscher M., Kelly J.M., Benešová-Schäfer M.
Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy
(2024) Pharmaceuticals, 17 (8), 1031.
DOI: 10.3390/ph17081031

Schacherl B., Maurer K., Schäfer M., Remde Y., Geyer F., Fried A., Happel S.A., Benešová-Schäfer M.
Concept validation of separations for thorium-based radionuclide generator systems for medical application
(2024) Frontiers in Nuclear Engineering, 3, 1379996.
DOI: 10.3389/fnuen.2024.1379996

Sallam M., Nguyen N.-T., Sainsbury F., Kimizuka N., Muyldermans S., Benešová-Schäfer M.
PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
(2024) Theranostics, 14 (8), 3043.
DOI: 10.7150/thno.92612

Sallam M., Mohammadi M., Sainsbury F., Nguyen N.-T., Kimizuka N., Muyldermans S., Benešová-Schäfer M.
Bibliometric and scientometric analysis of PSMA-targeted radiotheranostics: knowledge mapping and global standing
(2024) Frontiers in Oncology, 14, 1397790.
DOI: 10.3389/fonc.2024.1397790

Taş H., Bakos G., Bauder-Wüst U., Schäfer M., Remde Y., Roscher M., Benešová-Schäfer M.
Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?
(2024) Pharmaceuticals, 17 (4), 513.
DOI: 10.3390/ph17040513

Miederer M., Benešová-Schäfer M., Mamat C., Kästner D., Pretze M., Michler E., Brogsitter C., Kotzerke J., Kopka K., Scheinberg D.A., McDevitt M.R.
Alpha-Emitting Radionuclides: Current Status and Future Perspectives
(2024) Pharmaceuticals, 17 (1), 76.
DOI: 10.3390/ph17010076

2023

Bauder-Wüst U., Schäfer M., Winter R., Remde Y., Roscher M., Breyl H., Poethko T., Tömböly C., Benešová-Schäfer M.
Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals
(2023) Applied Radiation and Isotopes, 197, 110819.
DOI: 10.1016/j.apradiso.2023.110819

2022

Benešová M., Reischl G.
Production of radionuclides: Cyclotrons and reactors
(2022) Nuclear Medicine and Molecular Imaging: Volume 1-4, 1, pp. 52 - 65
DOI: 10.1016/B978-0-12-822960-6.00003-X

Benešová M., Guzik P., Deberle L.M., Busslinger S.D., Landolt T., Schibli R., Müller C.2
Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities
(2022) Molecular Pharmaceutics, 19 (3), pp. 963 - 973
DOI: 10.1021/acs.molpharmaceut.1c00932

Pazderová L., Benešová M., Havlíčková J., Vojtíčková M., Kotek J., Lubal P., Ullrich M., Walther M., Schulze S., Neuber C., Rammelt S., Pietzsch H.-J., Pietzsch J., Kubíček V., Hermann P.
Cyclam with a phosphinate-bis(phosphonate) pendant arm is a bone-targeting carrier of copper radionuclides
(2022) Dalton Transactions, 51 (24), pp. 9541 - 9555
DOI: 10.1039/d2dt01172g

2021

Klusa D., Lohaus F., Furesi G., Rauner M., Benešová M., Krause M., Kurth I., Peitzsch C.
Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response
(2021) Frontiers in Oncology, 10, art. no. 627379
DOI: 10.3389/fonc.2020.627379

Guzik P., Fang H.-Y., Deberle L.M., Benešová M., Cohrs S., Boss S.D., Ametamey S.M., Schibli R., Müller C.
Identification of a PET eadiotracer for imaging of the folate receptor-alpha – A potential tool to select patients for targeted tumor therapy
(2021) Journal of Nuclear Medicine, 62 (10)
DOI: 10.2967/jnumed.120.255760

Guzik P., Benešová M., Ratz M., Monné Rodríguez J.M., Deberle L.M., Schibli R., Müller C.
Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
(2021) European Journal of Nuclear Medicine and Molecular Imaging, 48 (4), pp. 972 - 983
DOI: 10.1007/s00259-020-04980-y

Kramer V., Fernández R., Lehnert W., Jiménez-Franco L.D., Soza-Ried C., Eppard E., Ceballos M., Meckel M., Benešová M., Umbricht C.A., Kluge A., Schibli R., Zhernosekov K., Amaral H., Müller C.
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
(2021) European Journal of Nuclear Medicine and Molecular Imaging, 48 (3), pp. 893 - 903
DOI: 10.1007/s00259-020-05022-3

Deberle L.M., Benešová M., Becker A.E., Ratz M., Guzik P., Schibli R., Müller C.
Novel Synthetic Strategies Enable the Efficient Development of Folate Conjugates for Cancer Radiotheranostics
(2021) Bioconjugate Chemistry, 32 (8), pp. 1617 - 1628
DOI: 10.1021/acs.bioconjchem.1c00198

2020

Deberle L.M., Benešová M., Umbricht C.A., Borgna F., Büchler M., Zhernosekov K., Schibli R., Müller C.
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
(2020) Theranostics, 10 (4), pp. 1678 - 1693
DOI: 10.7150/thno.40482

dos Santos J.C., Beijer B., Bauder-Wüst U., Schäfer M., Leotta K., Eder M., Benešová M., Kleist C., Giesel F., Kratochwil C., Kopka K., Haberkorn U., Mier W.
Development of novel PSMA ligands for imaging and therapy with copper isotopes
(2020) Journal of Nuclear Medicine, 61 (1), pp. 70 - 79
DOI: 10.2967/jnumed.119.229054

Roscher M., Bakos G., Benešová M.
Atomic nanogenerators in targeted alpha therapies: Curie’s legacy in modern cancer management
(2020) Pharmaceuticals, 13 (4), art. no. 76
DOI: 10.3390/ph13040076

Cardinale J., Roscher M., Schäfer M., Geerlings M., Benešová M., Bauder-Wüst U., Remde Y., Eder M., Nováková Z., Motlová L., Barinka C., Giesel F.L., Kopka K.
Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors
(2020) Journal of Medicinal Chemistry, 63 (19), pp. 10897 - 10907
DOI: 10.1021/acs.jmedchem.9b01479

Hennrich U., Benešová M.
[68Ga]Ga-DOTA-TOC: The first FDA-approved 68Ga- radiopharmaceutical for PET imaging
(2020) Pharmaceuticals, 13 (3), art. no. 38
DOI: 10.3390/ph13030038

Ermert J., Benešová M., Hugenberg V., Gupta V., Spahn I., Pietzsch H.-J., Liolios C., Kopka K.
Radiopharmaceutical Sciences
(2020) Clinical Nuclear Medicine: Second Edition, pp. 49 - 191
DOI: 10.1007/978-3-030-39457-8_2